title: Worldwide clinical data on efficacy and safety of ciprofloxacin.
abstract: During the clinical trials 8,861 patients have been treated with ciprofloxacin worldwide. 3,822 of the therapeutic courses were valid for analysis of efficacy according to FDA standards. The following dosages were usually administered: UTI: 100 to 500 mg twice daily orally or 100 mg twice daily intravenously; RTI: 250 to 1000 mg twice daily orally or 200 mg twice daily intravenously; septicemia: 200 mg intravenously twice daily; gonorrhea: 250 to 500 mg single tablet orally; all other infections: 500 to 1000 mg twice daily orally or 200 mg twice daily intravenously. Ciprofloxacin was administered to 762 courses of lower RTI, 88 courses of upper RTI, 108 courses of bacteremia, 766 courses of skin structure infection, 142 courses of bone and joint infections, 149 courses of intra-abdominal infections, 33 courses of gastrointestinal infections, 1,633 courses of UTI, 49 courses of pelvic infections, 279 courses of STD, mainly gonorrhea, and three courses of meningitis. The clinical response was resolution in 76%, improvement in 18% and failure in only 6%. Bacteriologic response by all sites evaluable: pathogens were eradicated from 74%, markedly reduced in 2%, persisted in 10%. Relapse occurred in 4% and reinfection was observed in another 6%. The overall response was favourable for 90% of the patients. Drug safety was established on a data base of 8,861 courses worldwide. The following side-effects according to COSTART terminology were observed: digestive 5%, metabolic nutritional 4.6%, central nervous 1.6%, skin 1.4%, hemic and lymphatic 1%, cardiovascular 0.4%, body as a whole 0.4%, urogenital 0.3%, special senses 0.3%, musculo-skeletal 0.1%, respiratory 0.08%. Several courses had more than one reaction. Thus the total incidence of side-effects for the treated patient population was 10.2%. Ciprofloxacin is a highly effective drug and a breakthrough in several areas of medical interest. It is relatively safe and side-effects are usually mild or moderate in intensity and transient.
authors.affiliation: Bayer AG, Pharma Forschungszentrum, Wuppertal 1.
authors.forename: P
authors.initials: P
authors.lastname: Schacht
authors.forename: G
authors.initials: G
authors.lastname: Arcieri
authors.forename: J
authors.initials: J
authors.lastname: Branolte
authors.forename: H
authors.initials: H
authors.lastname: Bruck
authors.forename: V
authors.initials: V
authors.lastname: Chyský
authors.forename: E
authors.initials: E
authors.lastname: Griffith
authors.forename: G
authors.initials: G
authors.lastname: Gruenwaldt
authors.forename: R
authors.initials: R
authors.lastname: Hullmann
authors.forename: C A
authors.initials: CA
authors.lastname: Konopka
authors.forename: B
authors.initials: B
authors.lastname: O'Brien
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D002939:Ciprofloxacin